05 July 2018
The global ophthalmic drugs market continues to grow rapidly with expected grow for 2018 at a CAGR of 4.4% in the first half of the forecast period. This is the findings of a new Ophthalmic report just published from Visiongain.
The market is estimated at $24bn in 2017, dominated by the retinal disorder drugs segment.
Key submarkets remain:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
With the key drugs, seeing the greatest revenues up to the end of the forecast period (2028) - This report analysis key drugs such as:
• Lumigan and Ganfort
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.
30 November 2020
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.